ABSTRACT
Intravenous immunoglobulin (IVIG) has a number of potential effects that may be beneficial in multiple sclerosis (MS): neutralization of circulating autoantibodies against myelin proteins, down-regulation of proinflammatory cytokines, functional blockade of Fc receptors on macrophages, suppression of inducer T cells and B cells, inhibition of complement activation and, in animal models, promotion of remyelination1,2.
